Cathie Wood's ARK Sells Roku and Roblox, Buys Arcturus Stock

Cathie Wood's ARK ETFs executed notable portfolio adjustments on September 25, 2025, significantly reducing exposure to tech names ROKU and ROBLOX while increasing holdings in the biotechnology firm ARCTURUS THERAPEUTICS. The ARKK ETF divested 21,592 ROKU shares ($2.12M) and 10,667 ROBLOX shares ($1.42M), continuing a trend of reduction in both. Conversely, the ARKG ETF acquired 26,536 ARCT shares ($542K), reflecting a bullish accumulation strategy in biotech. These moves underscore ARK's dynamic approach to disruptive innovation, signaling strategic shifts within its tech and biotech allocations.

Analysis

On September 25, 2025, Cathie Wood's ARK ETFs executed a clear strategic rotation, divesting from consumer technology and gaming while increasing exposure to biotechnology. The flagship ARKK fund continued a multi-day selling trend by shedding 21,592 shares of ROKU INC (NASDAQ:ROKU) for $2.12 million and 10,667 shares of ROBLOX CORP (NYSE:RBLX) for $1.42 million, signaling a sustained reduction in conviction for these names, a sentiment reflected in their respective negative scores of -0.7 and -0.6. Concurrently, the ARKG ETF demonstrated a bullish accumulation strategy by acquiring 26,536 shares of ARCTURUS THERAPEUTICS (NASDAQ:ARCT) for $542,661, reinforcing a pattern of recent purchases and a strong positive sentiment score of 0.7. These specific, high-velocity trades underscore ARK's dynamic management style and suggest a reallocation of capital within its 'disruptive innovation' thesis, moving away from specific tech platforms and toward perceived opportunities in the biotech sector.

Key Decisions for Investors

• Investors holding ROKU and RBLX should note the persistent selling pressure from a prominent growth-oriented manager like ARK, warranting a re-evaluation of the near-term thesis for these stocks.
• The consistent accumulation of ARCT by the ARKG fund signals strong bullish conviction, suggesting that investors focused on the biotech sector may want to conduct further due diligence on the company as a potential opportunity.
• Followers of ARK's strategy should recognize this as a tactical rotation from consumer tech and gaming into biotech, and may consider if their own portfolio alignment with ARK's forward-looking themes requires adjustment.